tert-butyl 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-propionate | 66340-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: tert-butyl 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-propionate
• 英文别名: N-(1-t-Butoxycarbonylethoxy)phthalimide；Propanoic acid, 2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-YL)oxy]-, 1,1-dimethylethyl ester, (2R)-；tert-butyl 2-(1,3-dioxoisoindol-2-yl)oxypropanoate
• CAS: 66340-70-3
• 化学式: C₁₅H₁₇NO₅
• 分子量: 291.304
• InChiKey: APBDROVGLRLEDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  396.1±44.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-propionate 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成 O-(1-t-butoxycarbonylethyl)hydroxylamine
  参考文献：
  名称：

  β-Scission of the N−O Bond in Alkyl Hydroxamate Radicals:  A Fast Radical Trap

  摘要：

  [GRAPHICS]dThe rate of the beta-scission of the N-O bond in the alkyl hydroxamate radical is faster than 2 x 10(8) s(-1). This reaction may be useful as a radical trap.

  DOI：

  10.1021/ol991392l
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 、 2-溴丙酸叔丁酯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 tert-butyl 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-propionate
  参考文献：
  名称：

  Effect of Optically Active Ethyl 2-Phthalimidooxypropionate on the Growth of Cress,Lepidium sativum

  摘要：

  研究了2-邻苯二甲酰亚胺氧基烷酸衍生物对水芹萌发和根生长的影响。由于2-邻苯二甲酰亚胺氧基丙酸酯最为有效，因此制备了光学活性的乙酯。生物测试结果显示，(S)-(-)-异构体比(R)-(+)-异构体表现出更强的活性。这一结果与结构类似、属于苯氧基和羟苯氧基丙酸酯类商业除草剂的情况相反，后者通常认为(R)-异构体是活性成分。

  DOI：

  10.1271/bbb.63.1831

文献信息

• MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  申请人：AULAKH Virender Singh

  公开号：US20150266867A1

  公开（公告）日：2015-09-24

  This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

  这项发明通常涉及公式I的抗菌化合物，如本文进一步描述，并其药用盐和制剂。在某些方面，该发明涉及使用这些化合物治疗由革兰氏阴性细菌引起的感染的方法。
• Cephem compounds, processes for their preparation and pharmaceutical compositions containing them
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0027599A2

  公开（公告）日：1981-04-29

  New cephem compounds of the formula: wherein R1 is amino or a protected amino group; R2 is hydrogen, lower alkyl which may be substituted with suitable substituent(s), lower alkenyl, lower alkynyl, cyclo(lower)-alkyl, cyclo(lower)alkenyl, or O containing 5-membered heterocyclic group substituted with oxo group(s); R3 is a group of the formula: wherein X is hydrogen or carbamoyl; and R' is -COO-; or R3 is 2-lower alkyl-5-oxo-6-hydroxy-2,5-dihydro-1, 2,4-triazinylthio; and R4 is carboxy or protected carboxy, and pharmaceutically acceptable salts thereof, and process for their preparation, and also a pharmaceutical composition comprising, as an effective ingredient, the above compound in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient. The invention also relates to the inter. mediate compounds and and their preparation,

  新的 cephem 化合物式： 其中 R1 是氨基或受保护的氨基； R2 是氢、可被适当取代基取代的低级烷基、低级烯基、低级炔基、环（低）烷基、环（低）烯基或被氧代基取代的含 O 的 5 元杂环基团； R3 是式中的基团： 其中 X 是氢或氨基甲酰基；以及 R' 是 -COO-；或 R3 是 2-低级烷基-5-氧代-6-羟基-2,5-二氢-1、 2，4-三嗪硫基；以及 R4是羧基或受保护的羧基，及其药学上可接受的盐和制备方法，以及一种药物组合物，其有效成分包括上述化合物与药学上可接受的、基本上无毒的载体或赋形剂。本发明还涉及中间体化合物 和 及其制备、
• Monobactam organic compounds for the treatment of bacterial infections
  申请人：Novartis AG

  公开号：US10369138B2

  公开（公告）日：2019-08-06

  This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.

  本发明一般涉及式 I 的抗菌化合物、 及其药学上可接受的盐类和制剂。在某些方面，本发明涉及使用此类化合物治疗感染（如革兰氏阴性细菌引起的感染）的方法。
• N- and C-terminal modifications of negamycin
  作者：B Raju、Kathleen Mortell、Sampathkumar Anandan、Hardwin O'Dowd、Hongwu Gao、Marcela Gomez、Corinne Hackbarth、Charlotte Wu、Wen Wang、Zhengyu Yuan、Richard White、Joaquim Trias、Dinesh V Patel

  DOI：10.1016/s0960-894x(03)00393-7

  日期：2003.7

  Negamycin 1 is a bactericidal antibiotic with activity against Gram-negative bacteria, and served as a template in an antibiotic discovery program. An orthogonally protected beta-amino acid derivative 3a was synthesized and used in parallel synthesis of negamycin derivatives on solid support. This advanced intermediate was also used for N- and C-terminal modifications using solution-phase methodologies. The N-terminal modifications have resulted in the identification of active analogues, whereas the C-terminal modifications resulted in complete loss of antibacterial activity. The N-methyl negamycin analogue, 19a, inhibits protein synthesis (IC50 = 2.3 muM), has antibacterial activity (Escherichia coli, MIC = 16 mug/mL), and is efficacious in an E. coli murine septicemia model (ED50 = 16.3 mg/kg). (C) 2003 Elsevier Science Ltd. All rights reserved.
• Cephem and cepham compounds, processes for their preparation, pharmaceutical compositions containing them
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0013762B1

  公开（公告）日：1985-03-13